The chipmaker spawned the term “patent troll” and has been highly critical of NPEs, but negative business headwinds mean that putting its world-class portfolio of IP assets to work is a no brainer
Several approaches have emerged under this banner, each offering advantages and disadvantages
The unfolding legal dispute between the ubiquitous social media giant and the billionaire with 100 million followers is set to become the legal battle of the year when it hits court in October
With significant revenue drop-offs from existing branded products set to decline steeply in the second half of this decade, major portfolio acquisitions are a priority for both companies
10 August 2022
The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November
10 August 2022
The portfolio covers a wide range of the tech produced by the Silicon Valley giant and will now be monetised by an entity named Tahoe Research Limited
08 August 2022
No commonly used valuation methods are much help at putting a number on an entire portfolio unless there is a specific transaction on the horizon. Cipher’s Nigel Swycher and Steve Harris suggest an original methodology to fill this gap
03 August 2022
The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months
29 July 2022
Employees are not necessarily always renumerated for their patented or patentable inventions. Therefore, employers are advised to take a number of steps to avoid disruptive issues over the ownership of intellectual property created by their employees.
27 July 2022
Recently implemented legislation gives the British government the ability to intervene in IP transactions
22 July 2022
IP transactions face difficulties when inventor employees leave a company, raising questions as to whether their inventions are owned by the company. Often, the type of employee and the jurisdiction in question are key factors.
20 July 2022
Royalty transactions are an increasingly attractive means of cashing in on life sciences innovation, and the returns can be significant
15 July 2022
The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space
04 July 2022
Get unlimited access to all IAM content
